Suchergebnisse - "Aliannejad, Rasoul"

PubPharm (7)

1

A placebo-controlled, crossover trial to investigate the efficacy of tiotropium bromide or placebo added to usual care in stable symptomatic post-hematopoietic stem cell transplantation (HSCT) bronchiolitis obliterans syndrome (BOS)

enthalten in: Trials | 2024

von Dini, N. | Khoshbin, A. | Aliannejad, R. | +4

2

Atorvastatin versus Placebo in ICU Patients with COVID-19 : Ninety-day Results of the INSPIRATION-S Trial

enthalten in: Thrombosis and haemostasis | 2023

von Talasaz, A. | Sadeghipour, P. | Bakhshandeh, H. | +64

3

Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS : a randomized controlled trial

enthalten in: Stem cell research & therapy | 2023

von Zarrabi, M. | Shahrbaf, M. | Nouri, M. | +19

4

Atorvastatin versus placebo in patients with covid-19 in intensive care : randomized controlled trial

enthalten in: BMJ (Clinical research ed.) | 2022

von INSPIRATION-S Investigators | Bikdeli, B. | Talasaz, A. | +64

5

Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit : 90-Day Results from the INSPIRATION Randomized Trial

enthalten in: Thrombosis and haemostasis | 2022

von Bikdeli, B. | Talasaz, A. | Rashidi, F. | +57

6

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit : The INSPIRATION Randomized Clinical Trial

enthalten in: JAMA | 2021

von INSPIRATION Investigators | Sadeghipour, P. | Talasaz, A. | +77

CommentIn: JAMA. 2021 Apr 27;325(16):1613-1615. - PMID 33734290

7

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19) : a randomized controlled trial

enthalten in: The Journal of antimicrobial chemotherapy | 2020

von Sadeghi, A. | Ali Asgari, A. | Norouzi, A. | +16

1
[1]